Status:
COMPLETED
Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors
Lead Sponsor:
AstraZeneca
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experiences by patients that receive AZD4877 on a ...
Eligibility Criteria
Inclusion
- Advanced solid tumors for which standard treatment doesn't exist or is no longer effective.
- Relatively good overall health other than your cancer.
Exclusion
- Poor bone marrow function (not producing enough blood cells).
- Serious heart conditions.
- Poor liver or kidney function.
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2008
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00389389
Start Date
September 1 2006
End Date
October 1 2008
Last Update
May 1 2009
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Denver, Colorado, United States
2
Research Site
Nashville, Tennessee, United States
3
Research Site
Houston, Texas, United States